ALEC - CIK 0001653087
Alector, Inc. trades as ALEC. In its fiscal 2025 annual report the company posted revenue of $21.05M, down 79.1% from the prior year and net income of -$143.00M. This page tracks Alector, Inc. through 581 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 8 fiscal years Alector, Inc.'s revenue grew from $3.73M to $21.05M, a compound annual growth rate of 24.1%. Net profit margin expanded from -869.6% to -679.5% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-14 |
| Major company event | 8-K | 2026-05-07 |
| Prospectus supplement | 424B5 | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| EFFECT | - | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
The largest companies sharing Alector, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Alector, Inc. reported revenue of $21.05M for fiscal year 2025, a decrease of 79.1% year over year.
In its latest fiscal year Alector, Inc. reported a net loss of $143.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.